Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 8/20 | 1.00 |
| ▸ | GRM2 | Q14416 | 4/20 | 1.00 |
| ▸ | GRM3 | Q14832 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 4/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | GRM8 | O00222 | 2/20 | 1.00 |
| ▸ | GRM6 | O15303 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | GRM5 | P41594 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | GRM1 | Q13255 | 1/20 | 1.00 |
| ▸ | PLCB1 | Q9NQ66 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4835874 | 1.00 | GRM4 (1.00) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL3125919 | 1.00 | GRM4 (1.00) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL935371 | 1.00 | GRM4 (1.00) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL719389 | 1.00 | GRM4 (1.00) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL2157698 | 1.00 | GRM4 (1.00) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL179741 | 1.00 | GRM4 (1.00) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL235442 | 1.00 | GRM4 (1.00) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL2916853 | 0.88 | GRM4 (0.78) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL4835681 | 0.88 | GRM4 (0.78) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL7271016 | 0.88 | GRM4 (0.78) | GRM4GRM2GRM3CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1038023-A1 | AGONISTS OF METABOTROPIC GLUTAMATE RECEPTORS AND USES THEREOF | THE UAB RESEARCH FOUNDATION (US) | 2000-09-27 | — | — | EP | claimed |
| US-6013672-A | ADMINISTERING TO AN INDIVIDUAL SUFFERING FROM HEAD, SPINAL CORD TRAUMA, STROKE AND EPILEPSY A THERAPEUTICALLY EFFECTIVE DOSE OF A METABOTROPIC GLUTAMATE RECEPTOR AGONIST | UAB RESEARCH FOUNDATION (US) | 2000-01-11 | — | — | US | claimed |
| US-6001581-A | Cation-based bioassay using human metabotropic glutamate receptors | SIBIA NEUROSCIENCES, INC. (US) | 1999-12-14 | — | — | US | claimed |
| WO-1999031268-A1 | AGONISTS OF METABOTROPIC GLUTAMATE RECEPTORS AND USES THEREOF | UAB RESEARCH FOUNDATION (US) | 1999-06-24 | — | — | WO | claimed |
| US-11938106-B2 | Treatment of tinnitus using glutamate receptor agonists | NORTHEAST OHIO MEDICAL UNIVERSITY (US) | 2024-03-26 | — | — | US | disclosed |
| US-20230038631-A1 | TREATMENT OF TINNITUS USING GLUTAMATE RECEPTOR AGONISTS | NORTHEAST OHIO MEDICAL UNIV (US) | 2023-02-09 | — | — | US | disclosed |
| US-20220142960-A1 | Compositions and Methods for Treating Metabolic Disorders | VEROSCIENCE LLC | 2022-05-12 | — | — | US | disclosed |
| US-20210251928-A1 | TREATMENT OF TINNITUS USING GLUTAMATE RECEPTOR AGONISTS | NORTHEAST OHIO MEDICAL UNIVERSITY | 2021-08-19 | — | — | US | disclosed |
| US-20190160059-A1 | Compositions and Methods for Treating Metabolic Disorders | VEROSCIENCE LLC (US) | 2019-05-30 | — | — | US | disclosed |
| EP-3311842-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | VeroScience LLC (US) | 2018-04-25 | — | — | EP | disclosed |
| WO-2017142543-A1 | TREATMENT OF TINNITUS USING GLUTAMATE RECEPTOR AGONISTS | NORTHEAST OHIO MEDICAL UNIVERSITY (US) | 2017-08-24 | — | — | WO | disclosed |
| CN-105579575-A | Compositions and methods for treating metabolic disorders | VEROSCIENCE LLC | 2016-05-11 | — | — | CN | disclosed |
| EP-0600741-A1 | Synthesis of kainic acid | ELI LILLY AND COMPANY (US) | 1994-06-08 | — | — | EP | disclosed |
| US-5319095-A | Synthesis of kainic acid | ELI LILLY AND COMPANY (US) | 1994-06-07 | — | — | US | disclosed |
| EP-0590789-A1 | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 1994-04-06 | — | — | EP | disclosed |
| US-5284957-A | Substituted 1H- or 2H-tetrazoles | ELI LILLY AND COMPANY (US) | 1994-02-08 | — | — | US | disclosed |
| US-5236908-A | Using adenosine antagonist | GENSIA PHARMACEUTICALS, INC. (US) | 1993-08-17 | — | — | US | disclosed |
| US-5196421-A | Treatment of neurological disorders | ELI LILLY AND COMPANY (US) | 1993-03-23 | — | — | US | disclosed |
| EP-0518530-A2 | Improvements in or relating to excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 1992-12-16 | — | — | EP | disclosed |
| US-5153196-A | Administering for reduction of neurotransmission in nervous system disorders | ELI LILLY AND COMPANY (US) | 1992-10-06 | — | — | US | disclosed |